Reduced Intensity Double Umbilical Cord Blood Transplantation

Median Time to Neutrophil Engraftment

The median number of days measured from the time of transplantation, until the first documented neutrophil engraftment. neutrophil engraftment is defined as the first of 3 consecutive days of absolute neutrophil count \> 500 neutrophils per microliter of blood.

Time frame: From the time of transplantation, until the time of neutrophil engraftment, median duration of 24 days

Median Time to Platelet Engraftment

The time to platelet engraftment is measured from the time of transplantation until the time of first documented platelet engraftment. Platelet engraftment is defined as a platelet count ≥ 20,000/µL for three consecutive measurements over three or more days. The first of the three days will be designated the day of platelet engraftment. Subjects must not have had platelet transfusions during the preceding 3 days or in the following 7 days after the day of engraftment, unless the platelet transfusion is being given specifically to achieve a platelet threshold to allow an elective invasive procedure, such as a central catheter removal.

Time frame: From the time of transplantation, until the time of platelet engraftment, median duration of 52 days

Number of Participants With Primary Graft Failure

Primary graft failure is defined as the failure to achieve an absolute neutrophil count (ANC) \>500/ µL by day 42, in the absence of relapse.

Time frame: From the time of transplantation until 42 days post transplantation

Rates of Grade II-IV and Grade III-IV Acute Graft Versus Host Disease (GVHD) at 100 Days

Acute GVHD is assessed using Consensus Criteria: Organ Classifications: * 0: No rash due to GVHD; Bilirubin \< 2 mg/dL; \< 500 mL diarrhea/ day * 1: Maculopapular rash \< 25% of body surface; Bilirubin 2-3 mg/dL; 500 to 999 mL diarrhea/ day or persistent nausea with histologic evidence of GVHD in stomach/ duodenum * 2: Maculopapular rash 25-50% of body surface; Bilirubin 3.1-6 mg/dL; 1,000 to 1,499 mL diarrhea/ day * 3: Maculopapular rash \> 50% of body surface; Bilirubin 6.1-15 mg/dL; 1,500 or more mL diarrhea/ day * 4: Generalized erythroderma with bullous formation; Bilirubin \> 15 mg/dL; Severe abdominal pain with or without ileus Overall Clinical Grade: * 0: No Stage 1-4 of any organ * I: Stage 1-2 rash and no liver or gut involvement * II: Stage 3 rash, or Stage 1 liver involvement, or Stage 1 gut involvement * III: None to Stage 3 skin rash with Stage 2-3 liver involvement, or Stage 2-4 gut involvement * IV: Stage 4 skin rash, or Stage 4 liver involvement

Time frame: 100 Days

The Rate of Chronic GVHD

Chronic Graft Versus Host Disease (GVHD) is assessed using the National Institutes of Health (NIH) consensus criteria.

Time frame: From the time of transplantation until the time of chronic GVHD onset, up to 1 year

100-day Treatment Related Mortality

The percentage of treatment related participant deaths within 100 days of receiving umbilical cord blood transplantation. All deaths in the absence of relapse of the primary malignancy will be considered treatment related mortality.

Time frame: 100 Days

Immune Reconstitution - Median CD4 Count at 12 Months

Time frame: 1 Year

Relapse-free Survival

The percentage of participants that have not died or had disease progression by two years. Relapse is defined by either morphological or cytogenetic evidence of the original malignancy consistent with pre-transplant features.

Time frame: 2 years

Overall Survival

The percentage of participants alive at two years

Time frame: 2 years

1 Year Relapse Rate

The percentage of participants that relapsed within 12 months. Relapse is defined by either morphological or cytogenetic evidence of the original malignancy consistent with pre-transplant features.

Time frame: 1 year

Rate of Post-transplant Lymphoma

The number of participants that were found to have lymphoma post-transplant.

Time frame: 2.5 years

Median Thrombopoietin Levels After Transplant

Time frame: 30 Days